Times Square Capital Management, LLC Arcus Biosciences, Inc. Transaction History

Times Square Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$17.23 - $37.73 $14.2 Million - $31 Million	-822,012 Closed	0 $0
Q1 2022 May 06, 2022	SELL	$28.92 - $41.83 $4.13 Million - $5.97 Million	-142,770 Reduced 14.8%	822,012 $25.9 Million
Q4 2021 Feb 04, 2022	BUY	$31.38 - $48.47 $9.81 Million - $15.1 Million	312,542 Added 47.92%	964,782 $39 Million
Q3 2021 Nov 08, 2021	SELL	$26.93 - $37.68 $950,629 - $1.33 Million	-35,300 Reduced 5.13%	652,240 $22.7 Million
Q2 2021 Aug 09, 2021	SELL	$22.75 - $35.77 $728,000 - $1.14 Million	-32,000 Reduced 4.45%	687,540 $18.9 Million
Q1 2021 May 12, 2021	SELL	$26.16 - $41.39 $2.82 Million - $4.46 Million	-107,730 Reduced 13.02%	719,540 $20.2 Million
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $399,500 - $760,460	-23,500 Reduced 2.76%	827,270 $21.5 Million
Q3 2020 Nov 06, 2020	SELL	$17.14 - $25.47 $584,474 - $868,527	-34,100 Reduced 3.85%	850,770 $14.6 Million
Q2 2020 Aug 07, 2020	BUY	$13.97 - $36.56 $12.4 Million - $32.4 Million	884,870 New	884,870 $21.9 Million

196

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $931M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Times Square Capital Management, LLC with notifications on news.